Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Loperamide Abuse Triggers Look At Potential Label Warning

This article was originally published in The Tan Sheet

Executive Summary

Monitoring of AERs prompts concern about the ingredient used in OTC anti-diarrheal products, CDER says a day after it noted adverse event reports in announcing concerns about a risk of serious bleeding linked to use of OTC antacid/aspirin products.

You may also be interested in...



Health Market News: Acetaminophen Prop 65 Report Posted; Loperamide Brands' Smaller Packaging

Brand-name loperamide OTCs will be packaged in single doses with no more than 48 mg per container; and California posts acetaminophen hazard identification for Prop 65 consideration.

FDA Looks At OTC Loperamide Packaging To Curb Opioid-Related Abuse

Ingredient in J&J's Imodium and numerous OTC generics acts on opioid receptors in the gut to slow movement in the intestines and decrease bowel movements, but dosing at much higher than recommended amounts can lead to serious problems including severe heart rhythm problems and death.

FDA Looks At OTC Loperamide Packaging To Curb Opioid-Related Abuse

Ingredient in J&J's Imodium and numerous OTC generics acts on opioid receptors in the gut to slow movement in the intestines and decrease bowel movements, but dosing at much higher than recommended amounts can lead to serious problems including severe heart rhythm problems and death.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS108380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel